Clinical Trial Update: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) [Phase 2]

View source ↗

Summary

Open-label extension study of Conatumumab and Ganitumab (AMG 479) in a Phase 2 trial for advanced solid tumors; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Carcinoid
• Colorectal Cancer
• Lymphoma
• Non-small Cell Lung Cancer
• Sarcoma
• Solid Tumors

Drugs mentioned

• Conatumumab (conatumumab)
• Ganitumab (AMG 479) (ganitumab)

Snippet

Sponsor: Amgen | Conditions: Advanced Solid Tumors, Carcinoid | Phase 2 | Status: COMPLETED | Results posted: 2021-02-21